{
    "nctId": "NCT04558034",
    "briefTitle": "The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer",
    "officialTitle": "The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Cryotherapy Effect, Peripheral Neuropathy, Nail Toxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 14,
    "primaryOutcomeMeasure": "Numbness,tingling,pain ,nail toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females 18 or older\n* Histologically confirmed diagnosis of breast cancer\n* Receiving neo-adjuvant or adjuvant dose-dense anthracycline (AC) plus taxane-based chemotherapy or paclitaxel in combination with trastuzumab and pertuzumab\n\nExclusion Criteria:\n\n* Prior taxane therapy\n* Prior oxaliplatin therapy\n* Non-English speaking\n* History of peripheral neuropathy, i.e., Buerger's disease\n* History of diabetes mellitus\n* Pre-existing peripheral neuropathy from other conditions, e.g., Raynaud's disease, Guillain-Barre, Miller Fisher Syndrome\n* Hand, nail or foot conditions, e.g., hand/foot syndrome, arthritis, hammer toe, carpal tunnel, bunions, deformities\n* Alcohol abuse (history/current)\n* Current medication usage of opioids, anti-depressants, anti-convulsants, glutamines, vitamin B12",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}